Therefore, as a hub gene influencing various metabolic outcomes, targeting SCD1 therapeutically is an attractive option to address multifaceted metabolic diseases, such as MASLD, cancer, and diabetes (6, 18, 19, 20). Here, SCD is linked to metabolic dysfunction-associated steatotic liver disease.